Nevro logo

NevroNYSE: NVRO

Profile

Sector:

Healthcare

Country:

United States

IPO:

06 November 2014

Next earnings report:

11 November 2024

Last dividends:

N/A

Next dividends:

N/A
$206.18 M
-94%vs. 3y high
53%vs. sector
-vs. 3y high
-vs. sector
-94%vs. 3y high
35%vs. sector
-95%vs. 3y high
13%vs. sector

Price

after hours | Fri, 01 Nov 2024 20:03:01 GMT
$5.53+$0.02(+0.36%)

Dividend

No data over the past 3 years
$104.16 M$93.07 M
$104.16 M-$19.57 M

Analysts recommendations

Institutional Ownership

NVRO Latest News

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy
prnewswire.com29 October 2024 Sentiment: POSITIVE

Analysis Marks the First Study of Spinal Cord Stimulation to Demonstrate Long-term, Significant, and Clinically Meaningful Reductions in HbA1c and Weight in Study Participants with Painful Diabetic Neuropathy and Type 2 Diabetes REDWOOD CITY, Calif. , Oct. 29, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the publication of new data in the Journal of Pain Research  demonstrating significant, durable pain relief and long-term and clinically meaningful reductions in hemoglobin A1c (HbA1c) and weight in study participants with painful diabetic neuropathy (PDN) and Type 2 diabetes who received 10 kHz high-frequency spinal cord stimulation (SCS) therapy.1 Globally, the number of people with diabetes has quadrupled in the last two decades2, and PDN impacts up to 25% of all people with diabetes.3 PDN can have significant impacts on the quality of life for people living with this condition, with symptoms like numbness, tingling/paresthesia, loss of protective sensation, impaired balance, and reduced response to sensory stimuli.4 Patients typically manage PDN with oral pain medications, but the efficacy of these medications is relatively low and can result in intolerable side effects.5 As a result, people with PDN suffer from significantly reduced health-related quality of life (HRQoL), impaired functionality and other comorbidities like sleep disorders, depression, and anxiety.6 The analysis evaluated 144 patients with Type 2 diabetes and refractory PDN who received 10 kHz SCS therapy during the SENZA-PDN randomized controlled trial (RCT), the largest RCT to evaluate SCS to treat PDN.

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
prnewswire.com16 October 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Oct. 16, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on October 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 26,088 shares of Nevro's common stock to five new non-executive employees to induce them to accept employment with Nevro.

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024
prnewswire.com10 October 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Oct. 10, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it will release its financial results for the third quarter of 2024 after the market closes on Monday, November 11, 2024.

Here's Why you Should Retain Nevro Stock in Your Portfolio Now
zacks.com26 September 2024 Sentiment: POSITIVE

Strength in NVRO's Senza Platform and business diversification plans raises optimism about the stock.

NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform
zacks.com25 September 2024 Sentiment: POSITIVE

Nevro announces the FDA approval and limited market release of HFX iQ with HFX AdaptivAI.

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation
prnewswire.com24 September 2024 Sentiment: POSITIVE

HFX AdaptivAI combines insights from over 100,000 patients and more than 100 million data points¹ and leverages artificial intelligence (AI) to deliver responsive and personalized pain relief in real time* REDWOOD CITY, Calif. , Sept. 24, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced the U.S. Food and Drug Administration (FDA) approval and limited market release of HFX iQ™ with HFX AdaptivAI™ – a responsive, personalized pain management platform powering the HFX iQ spinal cord stimulation (SCS) system.

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
prnewswire.com19 September 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on September 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 51,543 shares of Nevro's common stock to 21 new non-executive employees to induce them to accept employment with Nevro.

Nevro to Present at Wells Fargo 2024 Healthcare Conference
prnewswire.com28 August 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Aug. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in a "fireside chat" (question-and-answer) session at the Wells Fargo 2024 Healthcare Conference on Friday, September 6, 2024, beginning at 8:45 a.m.

Here's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com20 August 2024 Sentiment: POSITIVE

Strength in Nevro's (NVRO) Senza Platform raises optimism about the stock.

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
prnewswire.com14 August 2024 Sentiment: POSITIVE

REDWOOD CITY, Calif. , Aug. 14, 2024  /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on August 7, 2024, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 10,199 shares of Nevro's common stock to four new non-executive employees to induce them to accept employment with Nevro.

  • 1(current)
  • 2
  • 3

What type of business is Nevro?

Nevro Corp. is a global medical equipment company focused on providing innovative products that improve the quality of life for patients suffering from chronic pain. The company has developed the Senza spinal cord stimulation system, a scientifically based neuromodulation platform for treating chronic pain, and has also launched the latest product platform, Senza Omnia. The company launched Senza in the United States in May 2015, in some European countries since November 2010, and in Australia since August 2011. Currently, Senza is covered by all major insurance companies, and the patented hf10 therapy without sensory disturbances outperforms traditional spinal cord stimulation therapy, with hf10 therapy being nearly twice as successful in treating back pain and 1.5 times more successful in treating leg pain compared to traditional spinal cord stimulation therapy.

What sector is Nevro in?

Nevro is in the Healthcare sector

What industry is Nevro in?

Nevro is in the Medical Devices industry

What country is Nevro from?

Nevro is headquartered in United States

When did Nevro go public?

Nevro initial public offering (IPO) was on 06 November 2014

What is Nevro website?

https://nevro.com

Is Nevro in the S&P 500?

No, Nevro is not included in the S&P 500 index

Is Nevro in the NASDAQ 100?

No, Nevro is not included in the NASDAQ 100 index

Is Nevro in the Dow Jones?

No, Nevro is not included in the Dow Jones index

When was Nevro the previous earnings report?

No data

When does Nevro earnings report?

The next expected earnings date for Nevro is 11 November 2024